Trial Profile
A 16 Week, Open Label, Multi-centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms RAPID
- Sponsors United Therapeutics Corporation
- 01 Aug 2016 New trial record